Cargando…

Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies

BACKGROUND: Patients with migraine have an increased relative risk of cardio- and cerebrovascular events, and some migraine treatments may exacerbate this risk. The primary objective of this analysis was to determine whether the rate of cardiovascular adverse events was higher for patients with migr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Timothy R., Spierings, Egilius L. H., Cady, Roger, Hirman, Joe, Ettrup, Anders, Shen, Vivienne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903619/ https://www.ncbi.nlm.nih.gov/pubmed/34823467 http://dx.doi.org/10.1186/s10194-021-01360-1

Ejemplares similares

Eptinezumab for migraine prevention in patients 50 years or older
por: Martin, Vincent, et al.
Publicado: (2022)

Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine
por: McAllister, Peter, et al.
Publicado: (2022)

Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
por: Smith, Timothy R., et al.
Publicado: (2021)

Correction to: Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
por: Smith, Timothy R., et al.
Publicado: (2021)

Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab
por: Blumenfeld, Andrew, et al.
Publicado: (2022)

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
por: Ashina, Messoud, et al.
Publicado: (2020)

Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies
por: Pozo-Rosich, Patricia, et al.
Publicado: (2022)

Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2
por: Ashina, Messoud, et al.
Publicado: (2022)

Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
por: Lipton, Richard B., et al.
Publicado: (2020)

Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine
por: Buse, Dawn C., et al.
Publicado: (2022)

Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing
por: Dodick, David W., et al.
Publicado: (2020)

Patient‐identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient‐centered outcome
por: Lipton, Richard B., et al.
Publicado: (2021)

Eptinezumab for migraine
Publicado: (2022)

Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo‐controlled randomized clinical trials
por: Schim, Jack D., et al.
Publicado: (2022)

Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
por: Ailani, Jessica, et al.
Publicado: (2022)

Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
por: Ailani, Jessica, et al.
Publicado: (2023)

Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study
por: Barbanti, Piero, et al.
Publicado: (2022)

Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study
por: Cady, Roger, et al.
Publicado: (2022)

Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
por: Kudrow, David, et al.
Publicado: (2021)

Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication‐overuse headache
por: Marmura, Michael J., et al.
Publicado: (2021)

Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study
por: Cowan, Robert P., et al.
Publicado: (2022)

A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study)
por: Cady, Roger K, et al.
Publicado: (2015)

Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study
por: Silberstein, Stephen, et al.
Publicado: (2020)

Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2
por: Apelian, Rami, et al.
Publicado: (2022)

A Review of Eptinezumab Use in Migraine
por: Datta, Abhigyan, et al.
Publicado: (2021)

Cervical muscles in the pathogenesis of migraine headache
por: Shevel, Elliot, et al.
Publicado: (2004)

Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials
por: Lipton, Richard B., et al.
Publicado: (2022)

Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine
por: Spierings, Egilius LH, et al.
Publicado: (2017)

Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study
por: McAllister, Peter, et al.
Publicado: (2022)

Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial
por: Ashina, Messoud, et al.
Publicado: (2023)

Managing Migraine: Medication Overuse Headache and Treatment with Eptinezumab
por: Limberg, Nicole
Publicado: (2023)

Improving to Four or Fewer Monthly Headache Days Per Month Provides a Clinically Meaningful Therapeutic Target for Patients with Chronic Migraine
por: Kaniecki, Robert G., et al.
Publicado: (2023)

Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab
por: Scuteri, Damiana, et al.
Publicado: (2021)

Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine
por: Pederson, Susan, et al.
Publicado: (2021)

A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With Tx360® as Acute Treatment for Chronic Migraine
por: Cady, Roger, et al.
Publicado: (2015)

Population pharmacokinetic and exposure‐response analysis of eptinezumab in the treatment of episodic and chronic migraine
por: Baker, Brian, et al.
Publicado: (2020)

A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine
por: Munjal, Sagar, et al.
Publicado: (2017)

Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: Protocol for RESOLUTION—A phase 4, multinational, randomized, double-blind, placebo-controlled study
por: Jensen, Rigmor H., et al.
Publicado: (2023)

Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients
por: Baker, Brian, et al.
Publicado: (2021)

Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention
por: Morgan, Kelsey Woods, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9478bru6pd8q3jgl3vfle8i3gt